Groowe Groowe / Newsroom / ASND
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ASND News

Ascendis Pharma A/S American Depositary Shares

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

globenewswire.com
ASND

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

globenewswire.com
ASND

Liberty All-Star® Growth Fund, Inc. February 2026 Monthly Update

businesswire.com
NVDA AAPL GOOGL MSFT META AMZN CW OLLI AVGO LGN MPWR ARTV ASND LLY NVT CAT FTAI LOW PLTR TKO PINS UNH

Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy

prnewswire.com
GILD ASND ABBV

Ascend Named the Accounting Automation Partner for Combined Agents of America (CAA)

prnewswire.com
ASND

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

globenewswire.com
ASND

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

globenewswire.com
ASND

More Than 30 Million Americans Living with Rare Diseases

prnewswire.com
AMGN SNY AGIO ASND DVA INCY NVS PFE REGN UCB

Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update

businesswire.com
ASG NVDA AAPL GOOGL MSFT AMZN META OLLI STEP CW ARTV ASND MPWR SMTC VSEC PEN BRO NVT EXPE FITB MAR MS STRD AMD BAC GRMN NTRA ORCL

The Boston Globe to Host Rare Disease Summit

prnewswire.com
AZN ASND BMRA